Prelude Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-11,040
Closed -$147K – 1441
2026
Q2
$147K Buy
11,040
+200
+2% +$1.95K 0.01% 1046
2026
Q1
$101K Sell
10,840
-4,930
-31% -$42.9K 0.01% 1052
2025
Q4
$118K Sell
15,770
-7,230
-31% -$73.3K 0.01% 1159
2025
Q3
$200K Buy
23,000
+2,300
+11% +$13.7K 0.02% 955
2025
Q2
$76.8K Sell
20,700
-1,800
-8% -$6.33K 0.01% 936
2025
Q1
$72.7K Buy
+22,500
New +$106K 0.01% 1067
2023
Q1
– Sell
-12,631
Closed -$281K – 1278
2022
Q4
$281K Buy
+12,631
New +$195K 0.01% 813

Other funds holding FDMT

Prelude Capital Management's FDMT Position: Q3 2026 in Review

Prelude Capital Management sold out of 4D Molecular Therapeutics (FDMT) in Q3 2026, closing a stake of 11,040 shares — an estimated $147K sold.

Prelude Capital Management first reported a position in FDMT in Q4 2022 and held it in 7 quarters. The position peaked at $281K in Q4 2022. 162 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

  • Prelude Capital Management reported no remaining 4D Molecular Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Prelude Capital Management sold 11,040 4D Molecular Therapeutics shares in Q3 2026, an estimated $147K.
  • Prelude Capital Management first reported a position in 4D Molecular Therapeutics in Q4 2022 and held it in 7 quarters.
  • Prelude Capital Management's 4D Molecular Therapeutics position peaked at $281K in Q4 2022.
  • 162 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on Prelude Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.